Pharma Roundup: Pfizer and Wyeth, GlaxoSmithKline Overseas, and More

Pfizer and Wyeth: ramifications for the industry -- In a much-reported bit of news, Pfizer and Wyeth have been in merger talks for month, although there's no reason to believe the deal will necessarily go through. BNET's Jim Edwards has the details on what that would mean for the two companies. As for the rest of the industry, speculation is high that news of the talks could spark a consolidation wave. Could Bristol-Myers Squibb be next? [Source: Reuters]

GlaxoSmithKline invests in less-obvious emerging markets -- GSK CEO Andrew Witty has promised to push business into global markets, and the company just spent $667 billion for rights to certain UCB drugs in over 50 countries. China and India aren't among them, suggesting that GSK's strategy is more than expansion into only the largest markets. [Source: FiercePharma]

Genentech and Nordisk on Fortune best-for-employees list -- Novo Nordisk trumpeted its 57th place on the list in a press release, but Genentech quietly was rated seventh. They are the only pharma or biotech companies named. [Source: Fortune]

Mylan drug lab accident -- No one was killed or injured in an explosion at a Mylan plant in West Virginia. [Source: BusinessWeek, via Corey Nahman]